Dr. Foster and colleagues reply

New England Journal of Medicine

Volumn 374, Issue 17, 2016, Pages 1687-1688

  Foster, Graham R ^a   Mangia, Alessandra ^b   Sulkowski, Mark ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR;

CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LETTER; LIVER CIRRHOSIS; PRIORITY JOURNAL; VIRUS RESISTANCE; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; CARBAMATES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; SOFOSBUVIR;

EID: 84964990248     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1601160     Document Type: Letter

References (0)